ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $396,000 | -19.8% | 7,700 | -3.8% | 0.21% | +262.1% |
Q4 2019 | $494,000 | +79.0% | 8,000 | +105.1% | 0.06% | +205.3% |
Q4 2018 | $276,000 | -75.7% | 3,900 | -70.7% | 0.02% | -70.8% |
Q3 2018 | $1,136,000 | -67.8% | 13,300 | -69.5% | 0.06% | -71.1% |
Q1 2018 | $3,527,000 | +84.7% | 43,600 | -17.9% | 0.22% | +90.7% |
Q2 2017 | $1,910,000 | -59.0% | 53,100 | -64.9% | 0.12% | -60.0% |
Q1 2017 | $4,660,000 | -27.1% | 151,300 | -20.7% | 0.30% | -43.8% |
Q4 2016 | $6,391,000 | -24.6% | 190,800 | -40.1% | 0.52% | -23.6% |
Q3 2016 | $8,475,000 | +31.2% | 318,500 | +8.7% | 0.69% | +13.7% |
Q2 2016 | $6,462,000 | +202.2% | 293,100 | +302.6% | 0.60% | +179.6% |
Q1 2016 | $2,138,000 | +325.9% | 72,800 | +423.7% | 0.22% | +232.3% |
Q3 2015 | $502,000 | -64.5% | 13,900 | -61.2% | 0.06% | -69.5% |
Q3 2014 | $1,416,000 | +153.3% | 35,800 | +175.4% | 0.21% | +156.6% |
Q2 2014 | $559,000 | – | 13,000 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |